Table 1.
Baseline characteristics according to randomized groups and by trial.
| Characteristic | TREATMENT TRIAL | PREVENTION TRIAL | ||
|---|---|---|---|---|
| Enalapril | Placebo | Enalapril | Placebo | |
| (n = 1207) | (n = 1216) | (n = 2047) | (n = 2047) | |
| Age – years | 60 ± 10 | 61 ± 10 | 59 ± 10 | 59 ± 11 |
| Female | 226 (19) | 241 (20) | 229 (11) | 227 (11) |
| Black | 190 (16) | 172 (14) | 183 (9) | 197 (10) |
| eGFR – ml/min/1.73 m2 | 70.2 ± 19.9 | 68.7 ± 19.6 | 76.1 ± 18.5 | 76.3 ± 18.7 |
| eGFR < 60 ml/min/1.73 m2 | 403 (33) | 445 (37) | 420 (21) | 425 (21) |
| Diabetes | 293 (24) | 324 (27) | 313 (15) | 312 (15) |
| Hypertension | 508 (42) | 498 (41) | 748 (37) | 769 (38) |
| Ischemia | 849 (70) | 876 (72) | 1714 (84) | 1708 (83) |
| NYHA Functional Class | ||||
| NYHA Class I | 135 (11) | 133 (11) | 1359 (66) | 1372 (67) |
| NYHA Class II | 684 (57) | 684 (56) | 687 (34) | 672 (33) |
| NYHA Class III/IV | 388 (32) | 399 (33) | 1 (0) | 3 (0) |
| Hematocrit–% | 42.5 ± 4.8 | 42.0 ± 4.8 | 42.8 ± 4.4 | 43.1 ± 4.3 |
| Previous MI | 805 (67) | 792 (65) | 1658 (81) | 1640 (80) |
| Smoking, current | 276 (23) | 259 (21) | 463 (23) | 486 (24) |
| Diuretic Use | 1032 (86) | 1031 (85) | 329 (16) | 349 (17) |
Values are represented by mean ± standard deviation or n (%). GFR estimated using the Chronic Kidney Disease Epidemiology Collaboration equation. NYHA, New York Heart Association; eGFR, estimated glomerular filtration; MI, myocardial infarction